登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>CD20 >CD0-HF2H5

FITC-Labeled Human CD20 / MS4A1 Full Length Protein, His Tag (Nanodisc, SPR verified)

分子别名(Synonym)

MS4A1,CD20,MS4A-1

表达区间及表达系统(Source)

FITC-Labeled Human CD20 Full Length Protein, His Tag (CD0-HF2H5) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # P11836-1).

Predicted N-terminus: Met 1

Request for sequence

蛋白结构(Molecular Characterization)

CD20 Structure

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 35.2 kDa. The protein migrates as 26 kDa, 40 kDa and 70 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

Nanodiscs are a new class of model membranes that are being used to solubilize and study a range of integral membrane proteins and membrane-associated proteins. The Nanodisc bilayer is bounded by a membrane scaffold protein (MSP1D1) coat that confers enhanced stability and a narrow particle size distribution.

The nanodisc assembles from a mixture of full length membrane protein in detergent, phospholipid micelles and membrane scaffold protein(MSP1D1) upon removal of the detergent.

偶联(Conjugate)

FITC

Excitation source: 488 nm spectral line, argon-ion laser

Excitation Wavelength: 488 nm

Emission Wavelength: 535 nm

标记(Labeling)

The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.

内毒素(Endotoxin)

Less than 1.0 EU per μg by the LAL method.

纯度(Purity)

>85% as determined by SDS-PAGE.

制剂(Formulation)

Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

运输(Shipping)

This product is supplied and shipped with dry ice, please inquire the shipping cost.

存储(Storage)

Please protect from light and avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. The product MUST be stored at -70°C or lower upon receipt;
  2. -70°C for 3 months under sterile conditions.
*The isotype control of empty/mock nanodisc (Cat. No. APO-H51H3) is sold separately and not included in protein, you can follow this link for product information.
 

电泳(SDS-PAGE)

CD20 SDS-PAGE

FITC-Labeled Human CD20 Full Length Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-SPR

CD20 SPR

Obinutuzumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 23.4 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

CD20 SPR

Rituximab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 27.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

CD20 SPR

Ofatumumab captured on Protein A Chip can bind FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) with an affinity constant of 37.3 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 

活性(Bioactivity)-FACS

CD20 FACS

Flow cytometric analysis of Anti-CD20 CAR-293 cells staining with FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) at 1 μg/mL (1 μg/mL corresponds to labeling of 2.5e5 cells in a final volume of 100 µL), compared with negative control protein. FITC signal was used to evaluate the binding activity (QC tested).

Protocol

 

CAR阳性表达率检测(Evaluation of CAR expression)

FACS Analysis of Non-specific binding to PBMCs

CD20 CAR_T

Non-specificity of FITC-Labeled Human CD20 Full Length Protein, His Tag (Cat. No. CD0-HF2H5) binding to CD3+ cells present in human PBMC. 5e5 of human PBMCs were simultaneously stained with PE-labeled anti-CD3 antibody and FITC-Labeled Human CD20 Full Length Protein, His Tag (1 μg/mL corresponds to labeling of 5e5 cells in a final volume of 100 µL) and washed and then analyzed with FACS. Both FITC and PE positive signals was used to evaluate the non-specific binding activity to human CD3+ cells (QC tested).

 

背景(Background)

B-lymphocyte antigen CD20 is also known as B-lymphocyte surface antigen B1, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1 and MS4A1, is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last; it is present from late pro-B cells through memory cells, but not on either early pro-B cells or plasma blasts and plasma cells. It is found on B-cell lymphomas, hairy cell leukemia, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal B-cell immune response, specifically against T-independent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5); also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD20靶点信息
英文全称:B-lymphocyte antigen CD20
中文全称:B淋巴细胞抗原CD20
种类:Homo sapiens
上市药物数量:31详情
临床药物数量:103详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定